When was PredxBio founded?

PredxBio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is PredxBio located?

PredxBio is headquartered in Pittsburgh, United States.

How many employees does PredxBio have?

As of May 31, 2026, the latest employee count at PredxBio is 16.

Is PredxBio a funded company?

PredxBio is a funded company, having raised a total of $1.9M across 8 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Aug 24, 2018.

When was the latest funding round of PredxBio?

PredxBio's latest funding was a $***** Series B round on Aug 04, 2023, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.13B in funding in 2026 to date.

Where does PredxBio rank among its competitors?

PredxBio ranks 31st amongst 135 active competitors, of which 42 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Unnatural Products, which secured $45M in Mar, 2026.

Who are the top competitors of PredxBio?

PredxBio's top competitors include Seer, Biognosys and Peptris. Among them, Unnatural Products secured the most recent funding round in March, 2026.

PredxBio - 2026 Company Profile, Team, Funding & Competitors

PredxBio is a series B company based in Pittsburgh (United States), founded in 2017 by Jeffrey Fine and Michael Becich. It operates as a Developer of a platform for tissue-based biomarker discovery and clinical trials. PredxBio has raised $1.9M in funding from Newlin Investment. The company has 135 active competitors, including 42 funded and 13 that have exited. Its top competitors include companies like Seer, Biognosys and Peptris.

Company Details

Developer of a platform for tissue-based biomarker discovery and clinical trials. The platform applies spatial analytics and AI to identify tissue patterns. It enables biomarker discovery, patient stratification, and clinical trial design. The platform supports target discovery, translational readiness, and program-scale decision support.

Website: predxbio.com
Email ID: *****@predxbio.com

Key Metrics

Founded Year

2017

Location

Pittsburgh, United States

Stage

Series B

Total Funding

$1.9M in 8 rounds

Latest Funding Round

Series B, Aug 04, 2023, $*****

Investors

Newlin Investment & 2 more

Ranked

31^st among 135 active competitors

Employee Count

16 as on May 31, 2026

Similar Companies

Seer & 165 more

View PredxBio's full profile

PredxBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PredxBio, Inc. CIN: 822437048 , United States, Active		-	-	-

PredxBio has raised a total funding of $1.9M over 8 rounds. Its first funding round was on Aug 24, 2018. PredxBio has 3 institutional investors.

Here is the list of recent funding rounds of PredxBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 04, 2023	4445039	Series B	7470976	4846438	6880323	2223089
Jan 27, 2021	6861614	Series A	3334689	5679113	5789847	6757488
Jul 31, 2020	1845672	Series A	2029451	2697105	4194498	3142651

Access funding benchmarks and valuations. Sign up today!

View details of PredxBio's funding rounds and investors

The founders of PredxBio are Jeffrey Fine and Michael Becich.

Here are the details of PredxBio's key team members:

Jeffrey Fine: Co-Founder of PredxBio and founder of 1 other company.
Michael Becich: Founder of PredxBio, Inc. of PredxBio.

View details of PredxBio's Founder profiles and Board Members

PredxBio's employee count trend

PredxBio has 16 employees as of May 26. Here is PredxBio's employee count trend over the years:

Uncover PredxBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PredxBio include Seer, Biognosys and Peptris. Here is the list of Top 10 competitors of PredxBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Redalpine & 6 others	63/100
3rd	Peptris 2019, Bengaluru (India), Series A	Provider of AI-based proteomic data analysis software for drug discovery	$9.17M	Speciale Invest, Indian Angel Network Fund ... & 46 others	60/100
4th	Peptone 2016, Amsterdam (Netherlands), Series A	Provider of an AI based protein analysis platform for research and development	$42.5M	Bessemer Venture Partners, F-Prime Capital ... & 6 others	60/100
5th	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Two Bear Capital & 11 others	60/100
6th	Unnatural Products 2016, Santa Cruz (United States), Series B	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$83M	Merck Global Health Innovation Fund, Artis Ventures ... & 17 others	58/100
7th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	Lapam Capital, Deyi Capital & 8 others	57/100
8th	Atavistik 2021, Cambridge (United States), Series B	Developer of allosteric therapeutics for precision oncology and rare diseases	$260M	The Column Group, Nextech Invest & 3 others	55/100
9th	Avenue Biosciences 2023, Palo Alto (United States), Seed	Biotechnology company that employs protein engineering solutions	$15.6M	Voima Ventures, Balnord & 4 others	54/100
10th	Grove Biopharma 2020, Chicago (United States), Series A	Developer of AI-based drug modality platform for protein-based drugs	$34M	DCVC, Skydeck Capital & 10 others	54/100
31st	PredxBio 2017, Pittsburgh (United States), Series B	Developer of a platform for tissue-based biomarker discovery and clinical trials	$1.9M	Newlin Investment, Keiretsu Forum & 1 others	39/100